Chronic hepatitis B virus (HBV) infection has become a global public health problem, with 350 million carriers worldwide.
1 In areas where HBV is highly endemic, such as the Asia-Pacific region, chronic HBV infection is present in 80% to 90% of patients with hepatocellular carcinoma (HCC). Even in Western countries where HBV infection is less prevalent, it is still found in 16% to 60% of patients with HCC.
2 Several studies have shown that, with the use of lamivudine, a nucleoside analogue, the risk of development of HCC and other cirrhotic-related complications was significantly reduced in those with chronic infection
3-5 and even in cirrhotic patients.
6 However, there is a scarcity of data on the role of antiviral therapy after curative treatment for HCC.
7-9 Hepatectomy remains a standard curative treatment for HCC, but tumor recurrence is common, with approximately 50% of patients developing recurrent disease within 5 years.
10-12 Further surgical treatment was often limited by impaired function of the remnant liver,
13 and it remains uncertain whether antiviral therapy after initial treatment for HCC would prevent the remnant liver function from further deterioration and therefore increase the chances of these patients for future treatment. The aim of our study was to evaluate whether antiviral therapy after hepatectomy would improve the overall survival of patients with HBV-related HCC.